Metabolism drugs are primarily prescribed to treat various metabolic disorders including diabetes, hyperlipidemia, and other metabolic disorders. Metabolic disorders refer to a group of medical conditions that disrupt normal metabolism in the body. Some common medications used for metabolic disorders include insulin, metformin, statins, fibrates, and other drugs that help manage metabolic symptoms or medical conditions. Rising prevalence of metabolic disorders globally is a key factor fueling the demand for these drugs. For instance, according to the International Diabetes Federation, the prevalence of diabetes has nearly quadrupled since 1980, rising from 108 million to 422 million adults. Approximately 1.5 million deaths are directly attributed to diabetes each year. The global burden of diabetes is projected to reach 629 million people by 2045.
The global Metabolism Drugs Market is estimated to be valued at US$ 8169.16 Mn in 2023 and is expected to exhibit a CAGR of 7.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Growing prevalence of metabolic disorders is one of the major drivers bolstering the metabolism drugs market growth. According to the given report, the prevalence of diabetes has nearly quadrupled since 1980, rising from 108 million to 422 million adults globally. With rising obesity rates and sedentary lifestyles, the risk of developing diabetes and other metabolic disorders has increased significantly. This has enhanced the demand for effective drugs to manage various symptoms.
Another driver favoring the market growth is increasing adoption of metabolism drugs for weight management. Drugs like appetite suppressants and fat/carbohydrate blockers are gaining demand to assist in weight loss and maintenance efforts. For instance, orlistat, a pancreatic lipase inhibitor that prevents absorption of dietary fat, is one of the commonly used metabolism drugs for weight management. The growing obesity crisis worldwide has surged the demand for such weight loss therapy options.
One dominating segment in the Metabolism Drugs Market is inherited errors of metabolism. This segment accounts for over 30% of the total market share owing to the rising prevalence of inborn errors of metabolism disorders like phenylketonuria, storage disorders and fatty acid oxidation disorders. These disorders affect carbohydrate, fat and protein metabolism which if not treated can cause intellectual disability and even death in some cases. Hence, this segment generates highest demand for customized treatment therapies and diagnostic tests.
Political: Regulations supporting access to orphan drugs and funding for rare disease research by governments across major countries are boosting the adoption of customized metabolism drugs.
Economic: Rising health expenditure, growing per capita incomes and new healthcare investments are positively impacting the market growth.
Social: Increasing awareness about rare metabolic disorders and availability of new treatment options are encouraging more patients to seek medication.
Technological: Advancements in targeted drug delivery systems, molecular diagnostics and genetic testing techniques are facilitating development of personalized therapies.
The Global Metabolism Drugs Market Growth is expected to witness high. The global Metabolism Drugs Market is estimated to be valued at US$ 8169.16 Mn in 2023 and is expected to exhibit a CAGR of 7.6% over the forecast period 2023 to 2030.
North America currently dominates the market owing to presence of key players, favourable reimbursement policies and advanced healthcare infrastructure for rare disease research.
Key players operating in the are Central Admixture Pharmacy Services, Inc., Nephron Pharmaceuticals Corporation, QuVa Pharma, Olympia Pharmacy, ASP Cares, Fagron Compounding Pharmacies, Athenex, Inc., Avella Specialty Pharmacy, Atlas Pharmaceuticals, Empower Pharmacy, Carie Boyd’S Prescription Shop, Edge Pharma, Imprimis NJOF, LLC, IntegraDose Compounding services, LLC, Wells Pharma of Houston, LLC, US Compounding Inc., and SCA Pharma. Rapid penetration of advanced technologies and increasing research funding in Asia-Pacific is likely to boost the region’s market share in the coming years. Key players related content comprises Key players related content (Write very shorts about key players mention the given key players only).
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it